随着对免疫学理解的不断深入，越来越多的免疫疗法正在癌症治疗领域被探索和实施。 cGAS-STING 通路是先天免疫反应的关键要素，已被认为是癌症免疫治疗的关键。我们评估了五味子木脂素成分五味子素C（SC）对4T1和MC38荷瘤小鼠的抗肿瘤作用，并通过RNA测序、qRT-PCR和流式细胞仪研究了SC对cGAS-STING通路和抗肿瘤免疫的增强作用。细胞计数术。我们的研究结果表明，SC 显着抑制乳腺癌和结肠癌模型中的肿瘤生长。这种肿瘤生长的抑制归因于 I 型 IFN 反应的激活以及肿瘤内 T 细胞和 NK 细胞的增加。此外，SC 显着促进顺铂诱导的 cGAS-STING 通路激活。与顺铂单药治疗相比，SC与顺铂联合治疗对肿瘤生长表现出更大的抑制作用。化疗疗效的增强与 I 型干扰素反应的增强和抗肿瘤免疫力的增强有关。 SC通过增强I型IFN反应激活和增强抗肿瘤免疫来减少肿瘤生长并增加化疗敏感性，丰富了五味子抗肿瘤免疫的研究，为其在乳腺癌和结肠癌中的应用奠定了理论基础.版权所有 © 2024 杨、詹、赵、史、刘、伟、李、侯、穆、陈、郑、王、伟、肖、白。

With the advancing comprehension of immunology, an increasing number of immunotherapies are being explored and implemented in the field of cancer treatment. The cGAS-STING pathway, a crucial element of the innate immune response, has been identified as pivotal in cancer immunotherapy. We evaluated the antitumor effects of Schisandra chinensis lignan component Schisandrin C (SC) in 4T1 and MC38 tumor-bearing mice, and studied the enhancing effects of SC on the cGAS-STING pathway and antitumor immunity through RNA sequencing, qRT-PCR, and flow cytometry. Our findings revealed that SC significantly inhibited tumor growth in models of both breast and colon cancer. This suppression of tumor growth was attributed to the activation of type I IFN response and the augmented presence of T cells and NK cells within the tumor. Additionally, SC markedly promoted the cGAS-STING pathway activation induced by cisplatin. In comparison to cisplatin monotherapy, the combined treatment of SC and cisplatin exhibited a greater inhibitory effect on tumor growth. The amplified chemotherapeutic efficacy was associated with an enhanced type I IFN response and strengthened antitumor immunity. SC was shown to reduce tumor growth and increase chemotherapy sensitivity by enhancing the type I IFN response activation and boosting antitumor immunity, which enriched the research into the antitumor immunity of S. chinensis and laid a theoretical basis for its application in combating breast and colon cancer.Copyright © 2024 Yang, Zhan, Zhao, Shi, Liu, Wei, Li, Hou, Mu, Chen, Zheng, Wang, Wei, Xiao and Bai.